Drug Trial Radar · NCT03651765
Long Term Extension Trial of Setmelanotide
Last checked: Nov 20, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
205
Actual
Start
Jul 15, 2018
Primary completion
Jan 9, 2025
Study completion Jan 9, 2025
Sponsor
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the Melanocortin-4 (MC4) receptor in the leptin-melanocortin pathway.
Conditions
- Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions
SetmelanotideDrug
Once daily subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose up to 5.6 years
Locations
27 sites in 8 countries. Site status is shown where the registry gives one.
Synexus Clinical Research US, Inc. - Phoenix Southeast
Chandler, Arizona
Honor Health Research Institute
Scottsdale, Arizona
San Diego Wake Research
San Diego, California
University of Florida College of Medicine
Gainesville, Florida
Baystate Medical Center
Springfield, Massachusetts
University at Buffalo
Buffalo, New York
Duke University Medical Center
Durham, North Carolina
Wake Research
Raleigh, North Carolina
Obesity Institute, Geisinger Clinic
Danville, Pennsylvania
Childrens Hospital of Philadephia
Philadelphia, Pennsylvania
Synexus Clinical Research US, Inc.- Primary Care Associates, PC
Anderson, South Carolina
Wake Research TN
Chattanooga, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Seattle Children's Research Institute
Seattle, Washington
Marshfield Clinic Research Institute
Marshfield, Wisconsin
University of Alberta
Edmonton, Alberta, Canada
Hôpital Trousseau
Paris, France
Hôpital de la Pitié Salpêtrière
Paris, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
University of Leipzig
Leipzig, Germany
University of Ulm
Ulm, Germany
University General Hospital of Patras
Rio, Greece
Erasmus MC
Rotterdam, Netherlands
Universidad Autónoma de Madrid
Madrid, Spain
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Wellcome Trust-MRC Institute of Metabolic Science
Cambridge, United Kingdom
Hammersmith Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.